Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 23, 2023 - Issue 10: Triple negative breast cancer
Submit an article Journal homepage
1,189
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Triple-negative breast cancers

Steven A Naroda Women’s College Research Institute, University of Toronto, Toronto, Ontario, Canada;b Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, CanadaCorrespondence[email protected]
View further author information
&
Rebecca Dentc Department of Medical Oncology, National Cancer Center, SingaporeView further author information
Pages 1041-1043 | Received 31 Jul 2022, Accepted 06 Sep 2023, Published online: 14 Sep 2023

References

  • Davey MG, Keelan S, Lowery AJ, et al. The impact of chemotherapy prescription on long-term survival outcomes in early-stage invasive lobular carcinoma - a systematic review and meta-analysis. Clin Breast Cancer. 2022 Dec;22(8):e843–e849. doi: 10.1016/j.clbc.2022.09.005
  • Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000 Aug 17;406(6797):747–752.
  • Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010 Nov 11;363(20):1938–1948.
  • Metcalfe KA, Narod SA, Eisen A, et al. Genetic testing women with newly diagnosed breast cancer: what criteria are the most predictive of a positive test? Cancer Med. 2023 Mar [Epub 2022 Dec 21];12(6):7580–7587. doi: 10.1002/cam4.5515
  • Engel C, Rhiem K, Hahnen E, et al. German consortium for hereditary breast and ovarian cancer (GC-HBOC). Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history. BMC Cancer. 2018 Mar 7;18(1):265. doi: 10.1186/s12885-018-4029-y
  • Young SR, Pilarski RT, Donenberg T, et al. The prevalence of BRCA1 mutations among young women with triple-negative breast cancer. BMC Cancer. 2009 Mar 19;9(1):86. doi: 10.1186/1471-2407-9-86
  • Millikan RC, Newman B, Tse CK, et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat. 2008 May;109(1):123–139. Epub 2007 Jun 20. Erratum in: Breast Cancer Res Treat. 2008 May;109(1):141. Dressler, Lynn G [added]. PMID: 17578664; PMCID: PMC2443103. doi: 10.1007/s10549-007-9632-6
  • Kotsopoulos J, Gronwald J, Huzarski T, et al. And the hereditary breast cancer clinical study group. Tamoxifen and the risk of breast cancer in women with a BRCA1 or BRCA2 mutation. Breast Cancer Res Treat. 2023 Jul 11;201(2):257–264. doi: 10.1007/s10549-023-06991-3
  • Finch AP, Lubinski J, Møller P, et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol. 2014 May 20;32(15):1547–1553.
  • Brown LC, Salgado R, Luen SJ, et al. Tumor-infiltrating lymphocyctes in triple-negative breast cancer: update for 2020. Cancer J. 2021 Jan 1;27(1):25–31. doi: 10.1097/PPO.0000000000000501
  • Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429–4434.
  • Giannakeas V, Narod SA. A generalizable relationship between mortality and time-to-death among breast cancer patients can be explained by tumour dormancy. Breast Cancer Res Treat. 2019 Oct;177(3):691–703. Epub 2019 Jul 1. PMID: 31264063; PMCID: PMC6745044. doi: 10.1007/s10549-019-05334-5
  • Popovic LS, Matovina-Brko G, Popovic M, et al. Targeting triple-negative breast cancer: a clinical perspective. Oncol Res. 2023 May 24;31(3):221–238. doi: 10.32604/or.2023.028525
  • Guven DC, Yildirim HC, Kus F, et al. Optimal adjuvant treatment strategies for TNBC patients with residual disease after neoadjuvant treatment. Expert Rev Anticancer Ther. 2023 May;31:1–11.
  • Morganti S, Bychkovsky BL, Poorvu PD, et al. Adjuvant olaparib for germline BRCA carriers with HER2-negative early breast cancer: evidence and controversies. Oncology. 2023 Jul 5;28(7):565–574. doi: 10.1093/oncolo/oyad123
  • Schmid P, Cortes J, Dent R, et al. KEYNOTE-522 investigators. Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med. 2022;386(6):556–567. doi: 10.1056/NEJMoa2112651
  • Dixon-Douglas J, Loibl S, Denkert C, et al. Integrating immunotherapy into the treatment landscape for patients with triple-negative breast cancer. Am Soc Clin Oncol Educ Book. 2022 Apr;42(42):1–13. PMID: 35649211. doi: 10.1200/EDBK_351186

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.